Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 35 analyst ratings
Buy
Strong Buy 29%
Buy 26%
Hold 34%
Sell 9%
Strong Sell 3%

Bulls say

Amgen's strong financial outlook is bolstered by significant sales growth from its established product portfolio, including a notable 81% increase in Tavneos sales, which contributed to a total of approximately $716 million in U.S. sales for 2022. The company's recent acquisition of Horizon Therapeutics enhanced its rare-disease drug offerings with products like Tepezza, while its robust pipeline, featuring drugs such as MariTide and Imdelltra, is expected to drive long-term growth and revenue generation. Additionally, Amgen's sound cash position further supports its ability to invest in future growth opportunities, underpinned by a proven track record across various therapeutic areas including oncology, immunology, and rare diseases.

Bears say

Amgen faces significant risks that contribute to a negative outlook on its stock, primarily due to the potential for intensified competition in its core business, which may lead to market share erosion and pricing pressure on its established products. Additionally, there are concerns regarding lower-than-expected uptake rates for newly launched drugs and potential setbacks in the development and regulatory approval processes for its late-stage pipeline products and biosimilars. Management has indicated a potential mid-single-digit decline in pricing for its lead product, Repatha, which reflects broader concerns about the sustainability of revenue growth in the face of these challenges.

Amgen (AMGN) has been analyzed by 35 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 26% recommend Buy, 34% suggest Holding, 9% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Buy based on their latest research and market trends.

According to 35 analysts, Amgen (AMGN) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $286.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $286.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.